1416065-91-2

Upstream product

• 55362-80-6 9-bromononan-1-ol 
• 124388-97-2 9-bromononanal 
• 530084-79-8 8-(benzyloxy)-5-[(1R)-2-bromo-1-hydroxyethyl]quinolin-2(1H)-one 
• 530084-74-3 (R)-8-(benzyloxy)-5-(2-bromo-1-((tert-butyldimethylsilyl)oxy)ethyl)quinolin-2(1H)-one 
• 100331-89-3 8-benzyloxy-5-(2-bromoacetyl)-1H-quinolin-2-one 
• 93609-84-8 5-acetyl-8-benzyloxy-1H-quinolin-2-one 
• 1416069-24-3 3-(8-(1,3-dioxolan-2-yl)octyloxy)benzaldehyde 
• 1416069-22-1 (R)-quinuclidin-3-yl (3-(8-(1,3-dioxolan-2-yl)octyloxy)phenyl)(phenyl)methylcarbamate 
• 1416069-21-0 (3-(8-(1,3-dioxolan-2-yl)octyloxy)phenyl)(phenyl)methanamine 
• 1416069-20-9 2-(8-(3-(azido(phenyl)methyl)phenoxy)octyl)-1,3-dioxolane 
• 1416069-19-6 (3-(8-(1,3-dioxolan-2-yl)octyloxy)phenyl)(phenyl)methanol 
• 1416069-18-5 (3-(8-(1,3-dioxolan-2-yl)octyloxy)phenyl)(phenyl)methanone 
• 1415971-12-8 (R)-5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one hydrochloride 
• 1416069-23-2 (R)-quinuclidin-3-yl (3-(9-oxononyloxy)phenyl)(phenyl)-methylcarbamate 

Relevant academic research and scientific papers

Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD)

The targeting of both the muscarinic and β-adrenergic pathways is a well validated therapeutic approach for the treatment of chronic obstructive pulmonary disease (COPD). In this communication we report our effort to incorporate two pharmacologies into a single chemical entity, whose characteristic must be suitable for a once daily inhaled administration. Contextually, we aimed at a locally acting therapy with limited systemic absorption to minimize side effects. Our lung-tailored design of bifunctional compounds that combine the muscarinic and β-adrenergic pharmacologies by the elaboration of the muscarinic inhibitor 7, successfully led to the potent, pharmacologically balanced muscarinic antagonist and β2 agonist (MABA) 13.

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations with other pharmaceutical active ingredients.